$VTVT on watch, vTv Therapeutics Announces Positive Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes. double top at 4.10, beautiful channel forming. this is what im eyeing.